Claritas Pharmaceuticals, Inc.

Equities

CLAS.H

CA1806342061

Biotechnology & Medical Research

End-of-day quote Toronto S.E. Other stock markets 03:30:00 19/07/2022 am IST			5-day change	1st Jan Change
0.025 ^CAD	-16.67%		-.--%	-.--%

2021	Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	MT
2021	Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	CI

Kalytera Therapeutics, Inc. Appoints Robert S. Langer to the Scientific Advisory Board

June 24, 2016 at 02:00 am IST

Kalytera Therapeutics, Inc. announced the appointment of Dr. Robert S. Langer to Kalytera's Scientific Advisory Board. Dr. Langer is a David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT). He is a prolific biotechnologist, engineer, and inventor who is widely recognized for his contributions to the drug delivery and tissue engineering fields.

Latest news about Claritas Pharmaceuticals, Inc.

Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	18/21/18	MT
Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	26/21/26	CI
Claritas Pharmaceuticals : Reports Additional Data in Animal Model of Pulmonary Arterial Hypertension Treatment, R-107	21/21/21	MT
Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease	21/21/21	CI
Claritas Pharmaceuticals : 1-For-20 Share Consolidation Effective July 23	21/21/21	MT
Claritas Pharmaceuticals, Inc.(TSXV:CLAS) dropped from S&P/TSX Venture Composite Index	19/21/19	CI
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	29/21/29	CI
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	01/21/01	CI
Claritas Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	30/21/30	CI
Claritas Pharmaceuticals : In Agreement with CMAX Clinical Research for Phase 1 Clinical Study of Nitric Oxide-Releasing Drug, R-107	21/21/21	MT
Claritas Pharmaceuticals, Inc. Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107	21/21/21	CI
Claritas Pharmaceuticals, Inc.(TSXV:CLAS) added to S&P/TSX Venture Composite Index	19/21/19	CI
Claritas Pharmaceuticals : Announces Letter of Intent to Acquire Worldwide Rights to Develop R-107 Drug Compound	14/21/14	MT
Claritas Pharmaceuticals, Inc. entered into a binding Letter of Intent to acquire Exclusive Worldwide Rights of R-107 from Salzman Group Israel, Salzman Group Pty. Ltd. and Salzman Group, Inc. for $20.1 million.	14/21/14	CI
Kalytera Therapeutics, Inc. will Change its Name to Claritas Pharmaceuticals, Inc	12/21/12	CI
Kalytera Therapeutics, Inc. will Change its Ticker to CLAS from KLY	12/21/12	CI
Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients	08/21/08	CI
Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107	01/21/01	CI
Claritas Pharmaceuticals, Inc. Appoints Perenlei Enkhbaatar as an Independent Member of the Company’s Board of Directors, Effective Immediately	26/21/26	CI
Claritas Pharmaceuticals, Inc. Announces Board Changes	18/21/18	CI
Claritas Pharmaceuticals, Inc. Announces Completion of Canine Toxicology Studies	17/21/17	CI
Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107	12/21/12	CI
Claritas (Formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea to the Board of Directors	05/21/05	CI
Claritas (Formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of Covid-19 with Prophylactic R-107 Nasal Spray Designed	04/21/04	CI
Claritas to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections	03/21/03	CI

Chart Claritas Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâs products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CLARITAS PHARMACEUTICALS, INC.	-.--%	692K
MODERNA, INC.	+49.46%	54.63B
IQVIA HOLDINGS INC.	-5.30%	39.92B
LONZA GROUP AG	+37.35%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.92%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-21.84%	18.78B
UNITED THERAPEUTICS CORPORATION	+26.28%	12.21B
BIO-TECHNE CORPORATION	+1.78%	12.16B
MEDPACE HOLDINGS, INC.	+26.88%	11.94B

Other Biotechnology & Medical Research